Letters

Should asymptomatic haemochromatosis be treated?

BMJ 2000; 321 doi: https://doi.org/10.1136/bmj.321.7266.955/a (Published 14 October 2000) Cite this as: BMJ 2000;321:955

Alternative strategies to appropriate diagnosis need testing

  1. Jon Emery, Cancer Research Campaign primary care oncology research fellow (jon.emery@dphpc.ox.ac.uk),
  2. Peter Rose, general practitioner
  1. Imperial Cancer Research Fund General Practice Research Group, University of Oxford, Institute of Health Sciences, Oxford OX3 7LF
  2. Mill Stream Surgery, Oxford OX10 6RL
  3. George Eliot Hospital NHS Trust, College Street, Nuneaton, Warwickshire CV10 7DJ
  4. Honiton Group Practice, Marlpits Lane, Honiton, Devon EX14 2NY

    EDITOR—The contributions by Seamark and Hutchinson on the role of testing for and treatment of hereditary haemochromatosis highlight important issues about this disease and more generally about the clinical application of new genetic discoveries.1 Uncertainties about the definition of disease are highlighted—should it be based on genotype, abnormal biochemistry, or symptoms, and, consequently, at what point does a predisposition to disease become genuine disease? This is a reflection more generally of the genetics of disease predisposition and the management of disease risk. Inevitably if we treat the risk of a disease—be it by venesection for raised concentrations of ferritin or with tamoxifen in women with a family history of breast cancer—only a proportion of patients will benefit and some will be harmed.2

    We should be cautious about developing screening strategies for hereditary haemochromatosis for the general population. Proponents of population screening argue that it is common (based on a genetic definition of disease) and that prospective cohort studies show that early treatment results in normal life expectancy.3 For ethical reasons there will probably never be evidence from randomised controlled trials of venesection compared with watchful waiting in people with raised concentrations of ferritin. There is, however, sufficient uncertainty about expression of disease in C282Y homozygotes in the general population, and the role of gene/gene and gene/environment interaction in determining penetrance to postpone population …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe